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INTRODUCTION
The antimicrobial resistance in epidemic diseases 
like tuberculosis, typhoid or dysentery is relatively 
well characterised through nationwide surveillance 
systems that monitor these diseases and their aetiology, 
but not so for sporadic diseases such as cystitis (UTI) 
that can be caused by resistant bacteria, because they 
are not similarly monitored. Urinary tract infections 
are third ranked in the list of most common bacterial 
infections, and are the most frequent bacterial infections 
in women (1). Recurrent infections become a problem 
in 25% - 30% of women who experience an initial 
infection (2). Studies on antimicrobial susceptibility 
patterns show wide variations among communities, 
hospitals, and geographic regions (3). Studies reporting 
on antimicrobial resistance in uropathogenic bacteria 
in Kenya have originated from the Kenyatta National 
Referral and Teaching Hospital (4), and their findings 
may not truly capture the current antimicrobial 
resistance trends in other communities. This study 
was designed to identify prevailing uropathogens 
in the Kenyatta University community and their 
susceptibility to commonly available therapeutic 
agents. 
MATERIALS AND METHODS
The study adopted a cross-sectional survey research 
design, and the study population consisted of out 
patients with symptoms of UTls who sought treatment 
at the Kenyatta University Health Services Clinic. The 
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ABSTRACT
Objective: To determine the aetiological bacterial agents of urinary tract infections, 
within communities in Kenyatta University, and current resistance levels to commonly 
available therapeutic agents. 
Design: Cross-sectional survey research design. 
Setting: Kenyatta University Health Services Clinic, Nairobi. 
Subjects: Outpatients with symptoms of urinary tract infection within the six months 
study duration were observed. 
Results: Females were particularly prone to have confirmed cases of UTI. Escherichia 
coli were the principle aetiological agent accounting for 61.7% of the isolates. 
Other bacterial agents were Enterobacter agglomerans (18.7%), Citrobacter diversus 
(4%), Klebsiella pneumoniae (3.3%), Proteus spp. (2.1%), Pseudomonas spp. (0.1%), 
Staphylococcus saprophyticus (9.3%), and Streptococcus feacalis (0.7%). Over 60% of 
the Gram negative bacterial isolates were resistant to cotrimoxazole and ampicillin, 
39% resistant to augmentin and 25% were resistant to nalidixic acid. The ceftazidime 
was the most efficacious antimicrobial with an Escherichia coli resistance level of 
2.2% (P=0.05). Resistance to nitrofuraintoin, gentamicin, cefuroxime, norfloxacin and 
ciprofloxacin was demonstrated in less than 15% of the bacterial isolates. 
Conclusion: The cephalosporins, fluoroquinolones, nitrofurantoin and gentamicin have 
good efficacy against the uropathogenic bacteria and may be good therapeutic choices 
when culture results are unavailable. High resistance levels exist against cotrimoxa-
zole, ampicillin, augmentin, and nalidixic acid. These later antibiotics should therefore 
be used against the uropathogenic bacteria with caution. 
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study was approved by the Medical Officer incharge of 
the Kenyatta University Health Services and granted 
ethical clearance by the KEMRI/ National Ethical 
Review Committee. Informed patient’s consent was 
sought and obtained from the participants. 
 The clinic serves a community of approximately 
21,000 undergraduate students, 2,500 postgraduate 
students, and 2,436 employees and their dependants, 
representing a population that comes from across the 
country. 
 A total of 450 fresh midstream urine samples 
were collected in sterile universal bottles using 
previously described methods (5). The samples 
were examined macroscopically for physical 
characteristics such as turbidity, clarity, colour, 
and a biochemical analysis performed with the 
multistix (Bayer, USA), to test for pH, leukocytes, 
nitrite, protein, glucose, specific gravity, bilirubin, 
urobilinogen, ketones, and presence of blood. The 
urine samples were cultured on cystine-lactose 
electrolyte-deficient (CLED) agar (oxoid, UK) 
following the semi quantitative culture method (6). 
Bacterial growths of ≥105 colony forming units/ml of 
urine were identified using standard microbiological 
procedures. 
 The agar disk diffusion method was used to 
conduct the sensitivity testing (7). The bacterial 
inoculum was suspended in sterile saline (0.85% 
NaCI) and the turbidity adjusted to 0.5 McFarland 
standard. The bacterial suspension was streaked onto 
Mueller-Hintoin agar (Oxoid, UK), and tested against 
the following antibiotics concentrations, augmentin 
30µg, cefuroxime 30µg, nitrofurantoin 200µg, nalidixic 
acid  30µg, gentamicin 10µg, norfloxacin 5µg, 
cotimoxazole 75µg, ampicillin 25µg, ciprofloxacin 
5µg, and ceftazidime 30µg. The 100NH6 and 100KGL 
disks (Biotec Ltd, England) and for some antibiotics, 
individual disks (Oxoid, UK) were used to perform 
the susceptibility testing. 
 For the quality control of antimicrobial susceptibility 
testing, Escherichia coli strain ATCC 25922 was included 
in the tests alongside the isolates. 
Statistical analysis: Frequencies and percentages 
were used to present and summarise data. The chi-
square and Fisher’s exact test were used to compare 
categorical variables. A two tailed p-value of less than 
0.05 was considered to be statistically significant. 
RESULTS
Characteristics of the urine samples: Out of the 450 
fresh urine samples, 150 grew bacteria of clinical 
significance, making an isolation rate of 33.33 % 
(Table 1). Thirty one per cent females and 2% males 
had confirmed UTls (significant bacterial growth). 
There was a statistically significant association 
between confirmed UTIs and gender (χ2 = 64.8, 
df = 1, P < 0.05), with females more likely to have 
confirmed UTIs. Twenty eight per cent of the sampled 
patients had confirmed bacterial UTIs and turbid 
urine samples. There was a statistically significant 
association between culture confirmed UTIs and 
turbidity (χ2= 338, df= 1, P < 0.05). 
Characteristic of culture positive patients: Thirty 
eight of the 150 (25%) culture positive patients 
had recorded usage of antibiotics in the last three 
months prior to urine collection, with females 
constituting 36/150 (24%) and males 2/150 
(1.3%) of the patients with such history. However, 
there was no statistically significant association 
between gender and previous usage of antibiotics 
χ2= 0.161, df = 1, P > 0.05). Among the culture 
positive patients, the most commonly prescribed 
antimicrobial agents in the last three months 
prior to this survey (Table 2), were penicillins 
(amoxicillin, ampicillin and augmentin) at 47.5%, 
followed by fluoroquinolones (ciprofloxacin and 
norfloxacin) at 20.1%, and cotrimoxazole (7.5%). 
Ampicillin and cotrimoxazole had lower usage 
rates than the fluoroquinolones. The gentamicin 
and nitrofurantoin had minimal utilisation rates in 
the community at 0.7 % each. 
Aetiological agents: Eight genera of bacterial 
aetiological agents of UTI were isolated (Table 3). 
Ninety per cent were gram-negative bacilli such as 
Escherichia, Enterobacter, Citrobacter, Klebsiella, Proteus 
and Pseudomonas. The remaining 10% of the bacterial 
aetiological agents were Gram-positive cocci which 
included Staphylococcus and Streptococcus. 
Table 1
Patients gender, turbidity of urine samples and culture results
Gender  Turbid samples     Clear samples        Total (%) 
   Growth   No growth  Growth   No growth  
 No.  (%) No.  (%) No.  (%) No.  (%) No.  (%) 
Female  121   26.9  4   0.9 21   4.7  167  37.1 313 69.6 
Male  7      1.5  1   0.2  1    0.2  128  28.5  137 30.4 
Total  128   28.4  5   1.1  22   4.9  295  65.5  450 100 
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Table 2
Usage of antimicrobial agents among culture positive patients in the last three months   
Antimicrobial agent  Frequency  Antimicrobial  Antimicrobial 
          (%) use Class (%) use 
Penicillins      47.5 
   Augmentin  16  40   
   Ampicillin  3   7.5   
Cephalosporin       2.5 
   Cefuroxime  1   2.5   
Fluoroquinolone      20 
   Ciprofloxacin  5  12.5   
   Norfloxacin  3   7.5   
Aminoglycoside      10 
   Gentamicin  1   2.5   
   Minocycline  3   7.5   
Sulphonamide       7.5 
   Cotrimoxazole  3   7.5   
Nitrofurantoin  1  2.5  2.5 
Other  1   2.5   2.5 
Combined antimicrobial therapy  3   7.5  7.5 
Total  40  100  100 
Table 3
Aetiological bacterial isolates
Bacteria  No. (%)
Gram-negative bacilli  
   Escherichia coli  92 61.3 
   Enterobacter agglomerans  28 18.7
   Citrobacter diversus  6  4.0 
   Klebsiella pneumoniae  5  3.3 
   Proteus vulgaris  1  0.7 
   Proteus mirabilis  1  0.7 
   Proteus morganii 1  0.7 
   Pseudomonas  1  0.1 
Gram-positive cocci   
   Staphylococcus saprophyticus  14 9.3 
   Streptococcus feacalis  1 0.7 
Total  150 100 
Susceptibility pattern of the isolates: The isolates exhibited 
varying trends of susceptibility and resistance to 
the therapeutic agents (Table 4). Antibiotics that 
demonstrated good efficacy were; ceftazidime 
which was effective on over 90% of gram negative 
bacterial isolates, while gentamicin, ciprofloxacin, 
norfloxacin, and nitrofurantoin were effective to over 
80% of the isolates. The isolates were moderately 
sensitive to cefuroxime (over 70%), but exhibited low 
susceptibility (less than 55%) to nalidixic acid and 
augmentin among the E. coli strains and some other 
Gram negative bacteria. Ampicillin and cotrimoxazole 
exhibited very poor efficacy among the  Gram negative 
bacterial isolates (effective on less than 36%), although 
ampicillin demonstrated better efficacy (78%) on the 
Staphylococcus saprophyticus strains. 
Table 4
Susceptibility patterns for all the isolates
Antibiotic  E. coli          Enterococcus spp.        Citrobacter spp.   Staphylococcus 
 (n=92)       (n=28)        Klebsiella spp.   spp.   
      (n=11) (n=14)   
   S%  1%  R%  S%  1%  R%  S%  1%  R%  S%  1%  R% 
Augmentin  30.43  10.87  58.69  50  10.7  39.3  36.4  0  63.6  85.8  7.1  7.1 
Cefuroxime  70.65  17.39 11.96  85.7  10.7  3.6  72.7  0  27.3  92.9 7.1  0 
Ciprofloxacin  92.39  1.09  6.52  85.7  3.6 10.7  90.9  0  9.1  81.4 18.6  0 
Nitrofurantoin  85.87  8.70  5.43  82.1  7.2  10.7  63.6  18.2  18.2 85.7  0  14.3 
Nalidixic acid  55.44  13.04  31.52  71.4  3.6  25  45.4  36.4  18.2 28.6 0  71.4 
Gentamicin  90.21  1.09  8.69  92.9  0  7.1  81.8  0  18.2  78.6  0  21.4 
Ceftazdime  97.8  0  2.2  96.4  0  3.6  90.9  0  9.1  92.9 7.1  0 
Cotrimoxazole  10.8 72.17  86.95  17.9  0  82.1  27.3  9.1  63.6 57.1  0  42.9 
Ampicillin  16.30  1.09  82.61  35.7  0  64.3  9.1  9.1  81.8  78.6 7.1  14.3 
Norfloxacin  86.95  1.09  11.96  82.1  3.6  14.3 81.8 9.1  9.1 78.6 21.4 0 
S = Sensitive, I = intermediate susceptibility, R = Resistant 
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DISCUSSION
The isolation rate (33.33%) obtained in this study 
suggests that symptoms of UTI alone are not an 
adequate guide on which to base diagnosis and 
subsequent antimicrobial therapy decisions in 
urinary tract infections. This compares closely with 
an isolation rate of 39.5% obtained by a previous 
study in a teaching and referral hospital in Ethiopia 
(8). The large proportion of patients who presented 
with symptoms of UTI but did not yield positive 
bacterial cultures (66.7%) accentuate the need for 
laboratory diagnosis in UTls to avoid misdiagnosis 
and subsequent unnecessary treatment. 
 Turbidity in urine was however a good indicator 
for a culture positive UTI in this study (χ2 = 338, df 
= 1, P < 0.05). A previous study in outpatients with 
UTIs reported a 66% positive predictive value for 
finding a culture positive UTI from turbid samples (9). 
Therefore, turbidity in urine presents a tool that can 
be used by patients in presumptive self diagnosis of 
UTI. Among the confirmed UTI cases, females were 
more prone than males. Previous studies (10) have 
shown females at higher risk of UTIs. There is therefore 
need to sensitise females on clinical symptoms to aid 
in self diagnosis, importance in seeking immediate 
treatment, and knowledge of control measures. 
 Twenty five per cent of patients with confirmed 
UTIs had recorded usage of antibiotic in the last 
three months, but the association was not stastically 
significant ( χ2= 0.161, df = 1, P > 0.05). The study found 
that the flouroquinolones have a higher previous 
usage rate than the cotrimoxazole and ampicillin, 
which for long have been the recommended first 
line of treatment. This contrast with studies from the 
developed world (2) that show the later two drugs 
have high usage in UTI therapy. Cotrimoxazole and 
ampicillin are available over the counter in Kenya 
(14) and most bacteria have developed resistance. 
In addition, importation of counterfeit drugs which 
contain lower levels of active ingradients could be 
another contributory factor. The higher usage of 
fluoroquinolones recorded in this study may lead 
to an increase in resistance if stringent prescription 
measures are not observed. 
 Escherichia coli were the principle aetiological 
agent, followed by Enterobacter agglomerans, Citrobacter 
diversus, Klebsiella pneumoniae, and Proteus spp. The 
uropathogenic bacteria in this aetiological profile have 
been reported in the USA (11), in Dakar, Senegal (12), 
and in Tanzania (13). However, a notable variation 
in the aetiological profile from other studies carried 
out in referral hospitals (8, 13) is the prevalence of 
Enterobacter agglomerans as the second most frequent 
aetiological agent demonstrated in this study. This 
is a clear indication that variation in community 
acquired UTI, and antimicrobial susceptibility should 
be monitored constantly in order to capture any 
emerging resistance due to frequent gene transfers. 
 High resistance rates among the isolates to 
cotrimoxazole and ampicillin were observed, 
confirming earlier reported rates for these drugs at 
over 70% in community acquired bacterial infections 
in Kenya (4), and in Nigeria, Ethiopia, and Senegal 
(8, 12,14). The high resistance prevalence rates are 
a reflection of the widespread use of these two 
antibiotics over many years, combined with failure 
to respect ethics in antibiotic use in Africa (15). There 
is need to review the first-line therapy antimicrobials 
and consider alternative therapies. In contrast, the 
national resistance prevalence rates to ampicillin 
and cotrimoxazole in the USA has been reported at 
38% and less than 24% respectively (16), probably 
due to surveillance and observation of ethics in 
drug prescription and rational use. In the USA 
the cotrimoxazole is used as empiric therapy for 
uncomplicated UTI in some regions where resistance 
is 20% and less (16). 
 The E. coli bacterial isolates exhibited a resistance 
rate of 12% to cefuroxime, a finding that is significantly 
higher than that of below 5% reported in previous 
studies in the 1990s (16,21). It is evident that with 
use over the years, resistance to this drug is on the 
rise. This could be the outcome of widespread self- 
medication and abuse of ethics by pharmacists in over 
the counter sales. Only 2.2% of the bacterial isolates 
demonstrated resistance to ceftazidime. Ceftazidime 
is an expensive antibiotic, which restricts its use and 
abuse (15). Both cefuroxime and ceftazidime may be 
considered as alternative therapy for resistant UTIs 
in the community. 
 The newer fluoroquinolones,  namely 
ciprofloxacin and norfloxacin that form the main 
line of therapy for UTIs, show a good but decreasing 
in vitro efficacy for the isolates, with resistance 
prevalence rates of about 10%, a finding reported in 
other countries (8). In some African countries, higher 
resistance rates of over 20% have been reported (14). 
However, markedly higher susceptibility has been 
reported in Europe and USA, where resistance rates 
are 2.6% and below (16). The lower resistance levels 
in Europe can be traced to prudent antibiotic use (17). 
The Gram negative bacterial isolates exhibited the 
highest resistance (31.5%) to nalidixic acid, an older 
quinolone. This finding is markedly different from 
that of less than 10% reported in previous studies 
(4). The increasing resistance to flouroquinolones 
may be due to an increase in prescribing practice, 
which calls for continuous monitoring of resistance 
and restricting their use in therapy of uncomplicated 
UTIs in order to preserve their effectiveness. 
 Gentamicin, an aminoglycoside, showed high 
efficacy for all the isolates. This has been reported 
in previous studies in Africa (4, 8), and in the USA 
(1). This antibiotic has been in use for over 50 years 
and still retains potency. However, there is limited 
usage of this drug in the study community probably 
because its administration as an injection drug may 
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not be desirable to many patients. The limited usage 
has delayed the emergence and spread of resistance 
to the drug. 
 Nitrofurantoin showed good susceptibility (over 
82%) for most bacterial isolates, although resistance 
rate of less than 10% had been reported in previous 
studies in Kenya (4). Nitrofurantoin is one of the oldest 
urinary antibacterial agents still in use. This antibiotic 
is thought to have many modes of action that delay 
emergence of resistance and co-resistance. This study 
observed that nitrofuraintoin is rarely prescribed in 
the community studied, which may also explain the 
low resistance prevalence rates despite availability 
in the market for a longer duration. 
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